Deverra Therapeutics

Seeking Remission For All

Print
Follow Claim My Business
Min Investment
$500
Location
SEATTLE, WA
Expected Close Date
September 03, 2024
Target Raise
$15.00K-$1.24M
Security Price
$2.09
Website
deverratx.com
Number of Employees
12
Cash
$264,595
Revenue
$1,677,259
Short Term Debt
$7,222,643
Cost of Goods
$1,677,259
Long Term Debt
$0
Net Income
$1,672,096

Company Description

Deverra is a clinical-stage biotech company committed to providing universal donor treatments, opening doors for accessible & affordable immune cell therapies for cancer & other life-threatening illnesses.

Key Deal Facts

Deverra’s pioneering technology aims to reinvent the way immune cell therapies are developed & delivered. Our cell therapies are cost effective, safe & can be readily available – striving to make remission a reality for all patients.

Dilanubicel, Deverra’s lead clinical asset, has shown significantly improved remission rates in a phase 2 leukemia clinical trial with 184 patient infusions. Now, we’re just one clinical trial away from potential FDA approval.
Amount Raised : $975,776
Reveal the Score by Voting
_
0
Business Idea
Business Traction
Management Team
Valuation

Research Reports

No reports have been submitted

Become a Reporter

0 Comments